<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889834</url>
  </required_header>
  <id_info>
    <org_study_id>K180405J</org_study_id>
    <nct_id>NCT03889834</nct_id>
  </id_info>
  <brief_title>Biological Parameters Changes After Autologous Blood Transfusion of Red Blood Cells (200 ml) in Healthy Volunteers.</brief_title>
  <acronym>AUTOT-SPORT</acronym>
  <official_title>Modification of Biological Parameters After Autologous Blood Transfusion of a Small Volume of Packed Red Blood Cells (200 ml) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Anti-Doping Agency (AFLD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Anti-doping Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GR-Ex executive comitee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Transfusion Sanguine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if differences between samples of subjects obtained
      before autologous blood transfusion or samples of non-transfused subjects and samples of
      subjects after autologous blood transfusion can be identified. Analyses performed will focus
      on the morphological and biochemical parameters of red blood cells and associated
      microparticles. The final goal would be to find markers of autologous blood transfusion, that
      could be used to identify such doping practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology and study design:

      Pr Olivier Hermine, coordinator of the laboratory of Excellence GR-EX regrouping EFS
      (Etablissement Français du Sang) and INTS (Institut National de Transfusion Sanguine)
      partners, and leader of the Centre d'Investigation Clinique (CIC) IMAGINE (Hospital Necker,
      Paris, France) will assure the promotion of the clinical study for Paris Hospital consortium
      AP-HP (assistance Publique-Hôpitaux de Paris).

      To reproduce two potential scenarios of autologous transfusion by an athlete, 1 bag of blood
      packed red blood cells (after leuko deprivation and centrifugation) will be either stored at
      4°C or frozen at -80°C after addition of 40% w/v glycerol. Reinfusion will be performed 31
      days later.

      A clinical randomized double-blinded two-phase study will be conducted. Volunteers will be
      separated in 3 groups:

        -  Group 1: Volunteers with regular sports activities without Autologous Blood Transfusion
           (ABT)T (n=10)

        -  Group 2: Volunteers with regular sports activities receiving a 200ml ABT with
           refrigerated blood (n=10)

        -  Group 3: Volunteers with regular sports activities receiving a 200ml ABT with frozen
           blood (n=10)

      To ensure volunteers safety, collection, preparation and pretransfusion blood testing will be
      performed by EFS at hospital Pitié-Salpêtrière (Paris, France). ABT as well as collection of
      samples will be performed at the IMAGINE Institute (Paris, France). Blood samples will be
      collected before blood removal, the day of the ABT just before reinfusion and after 3 hours,
      8 hours, 24 hours and 48 hours post-ABT. To perform all the experiments 25ml blood (4x 5 ml
      BD Vacutainer EDTA tubes) will be taken at each time point:

      1 will be dispatched to the French anti-doping laboratory for haematological analysis
      (Châtenay-Malabry, France), 2 to the EFS (Créteil, France) for RBC and MPs morphological
      characterization and quantification (using antigen markers, band 3 on the surface of MPs), 2
      to INTS for MPs isolation, characterization (band 3 on the surface of MPs and RBC) and for
      proteomic analysis and Western-Blot.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>erythrocytes (/µL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>hemoglobin (g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Hematocrit (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Mean corpuscular volume (fL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Reticulocyte by Sysmex XT2000i analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation in Red blood cells morphology</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>By amnis imaging flow cytometryProteins in Red blood cells (Wblot/ELISA/FACS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in expression of cell surface proteins in red blood cells transfusion</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Western blot /ELISA/ fluorescence-activated cell sorting of red blood cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in microparticles detected in plasma</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>fluorescence-activated cell sorting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in phthalate in urine</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Assay by LC-MS/MS in urine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>The Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Autotransfusion: blood stored at 4 ° C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at 4 ° C for 31 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autotransfusion: blood stored at -80°C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at -80°C for 31 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls not transfused</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>no transfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Blood Transfusion</intervention_name>
    <description>Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days</description>
    <arm_group_label>Autotransfusion: blood stored at -80°C</arm_group_label>
    <arm_group_label>Autotransfusion: blood stored at 4 ° C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No transfusion</intervention_name>
    <description>no transfusion</description>
    <arm_group_label>Controls not transfused</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male between 18 and 35 years old

          -  Without health problem nor disease requiring regular medical treatment

          -  free from any intercurrent acute pathology over 7 days

          -  healthy volunteers who have regularly sport activity, able to have blood sample and is
             out-of-competition during the research

          -  Subject who did not practiced a competition (or exhaustive training ) 3 days before
             the blood sample and the autotransfusion

          -  Affiliated to a social security regimen

        Exclusion Criteria:

          -  - subject with contraindication for drawing blood

          -  Subject with medical pathology contraindicating sport practice - Subject under
             treatments or drugs in the Prohibited List updated each year by the World Anti-Doping
             Agency.

          -  Subject with physical or mental disability or restriction of liberty that would
             prevent autotransfusion

          -  Subject without to a social security regimen

          -  Subject under guardianship or curatorship

          -  Subject participating in any Interventional study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Hermine, MD</last_name>
    <phone>+33 (0)1 44 49 51 98</phone>
    <email>olivier.hermine@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie Jolaine, Manager</last_name>
    <phone>: +33 (0)1 42 19 28 79</phone>
    <email>valerie.jolaine@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Etablissement Français du Sang IDF, Hôpital de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <state>IDF</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre Gameiro, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous transfusion</keyword>
  <keyword>doping</keyword>
  <keyword>blood markers</keyword>
  <keyword>detection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

